Ronald W Schell

US Patent:

20020071851, Jun 13, 2002

Filed:

Aug 14, 2001

Appl. No.:

09/930657

Inventors:

Jon Korshus - Minneapolis MN, US
Paul Runnels - Floyd IA, US
Richard Sharpee - Green Oaks IL, US
Ronald Schell - Madison WI, US
Steven Callister - Onalaska WI, US

Assignee:

Solvay Animal Health, Inc.

International Classification:

A61K039/02
C12N001/21

US Classification:

424/234100, 435/252300

Abstract:

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated , an adjuvant in an amount effective to enhance the immunogenicity of the inactivated isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first Borrelia burgdorferi isolate and a second, non-crossprotective isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third . Further provided is a bacterin which includes effective immunizing amounts of two non-crossprotective isolates of inactivated and one or more antigenic subunits from the non-crossprotective isolates, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated and antigenic subunits and a suitable carrier.

US Patent:

20050042235, Feb 24, 2005

Filed:

Jun 11, 2004

Appl. No.:

10/866512

Inventors:

Jon Korshus - Lakeville MN, US
Paul Runnels - Floyd IA, US
Richard Sharpee - Green Oaks IL, US
Ronald Schell - Madison WI, US
Steven Callister - Onalaska WI, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K039/02
C12N001/20

US Classification:

424234100, 435252300

Abstract:

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated , an adjuvant in an amount effective to enhance the immunogenicity of the inactivated isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first isolate and a second, non-crossprotective isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third . Further provided is a bacterin which includes effective immunizing amounts of two noncrossprotective isolates of inactivated and one or more antigenic subunits from the non-crossprotective isolates, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated and antigenic subunits and a suitable carrier.

US Patent:

20080026009, Jan 31, 2008

Filed:

Jul 9, 2007

Appl. No.:

11/774968

Inventors:

Jon Korshus - Minneapolis MN, US
Paul Runnels - Floyd IA, US
Richard Sharpee - Green Oaks IL, US
Ronald Schell - Madison WI, US
Steven Callister - Onalaska WI, US

International Classification:

A61K 39/02
A61P 31/04

US Classification:

424234100

Abstract:

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated , an adjuvant in an amount effective to enhance the immunogenicity of the inactivated isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first isolate and a second, non-crossprotective isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third . Further provided is a bacterin which includes effective immunizing amounts of two non-crossprotective isolates of inactivated and one or more antigenic subunits from the non-crossprotective isolates, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated and antigenic subunits and a suitable carrier.

US Patent:

20110256178, Oct 20, 2011

Filed:

Apr 21, 2011

Appl. No.:

13/091824

Inventors:

Jon B. KORSHUS - Lakeville MN, US
Paul L. Runnels - Floyd IA, US
Richard L. Sharpee - Green Oaks IL, US
Ronald F. Schell - Madison WI, US
Steven M. Callister - Onalaska WI, US

International Classification:

A61K 39/02
A61P 31/04
A61P 37/04

US Classification:

4242341

Abstract:

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated , an adjuvant in an amount effective to enhance the immunogenicity of the inactivated isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first isolate and a second, non-crossprotective isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third . Further provided is a bacterin which includes effective immunizing amounts of two non-crossprotective isolates of inactivated and one or more antigenic subunits from the non-crossprotective isolates, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated and antigenic subunits and a suitable carrier.

US Patent:

53858263, Jan 31, 1995

Filed:

Aug 9, 1993

Appl. No.:

8/088590

Inventors:

Ronald F. Schell - Madison WI
Steven M. Callister - Onalaska WI

Assignee:

Gundersen Medical Foundation, Ltd. - Lacrosse WI

International Classification:

C12Q 100
C12Q 102
G01N 3353

US Classification:

435 732

Abstract:

A method of performing an assay to determine whether a patient has been exposed to or infected by Borrelia burgdorferi is disclosed which comprises collecting serum from the patient; preparing a sample mixture comprising a portion of the patient's serum and an inoculum of viable Borrelia burgdorferi organisms; incubating the sample mixture; determining the number of viable organisms remaining in the sample mixture after incubation; and comparing the number with the quantity of viable organisms remaining in a control. An assay kit is also disclosed which is useful for determining whether a patient has been exposed to or infected by Borrelia burgdorferi. The kit contains reagents necessary to practice the assay method disclosed herein. In its broadest form, the kit comprises an inoculum of viable Borrelia burgdorferi organisms. The kit can also contain an aliquot of normal serum, an aliquot of BSK medium and/or an aliquot of complement.

US Patent:

63160056, Nov 13, 2001

Filed:

Jan 21, 1997

Appl. No.:

8/722013

Inventors:

Jon B. Korshus - Minneapolis MN
Paul L. Runnels - Floyd IA
Richard L. Sharpee - Green Oaks IL
Ronald F. Schell - Madison WI
Steven M. Callister - Onalaska WI

Assignee:

Solvay Animal Health, Inc. - Mendota Heights MN

International Classification:

A61K 3902
A61K 39116
A61K 3900
A01N 6300

US Classification:

4242341

Abstract:

A bacterin including effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi isolates and a suitable carrier is provided herein. The bacterin may also contain a third non-crossprotective isolate. A bacterin including effective immunizing amounts of an antigenic subunit derived from a first Borrelia burgdorferi isolate and a second, non-crossprotective Borrelia burgdorferi isolate, an adjuvant in an amount effective to enhance the immunogenicity of the antigenic subunits and a suitable carrier is also provided. The bacterin may also contain an effective immunizing amount of an antigenic subunit of a third Borrelia burgdorferi. Further provided is a bacterin which includes effective immunizing amounts of two non-crossprotective isolates of inactivated Borrelia burgdorferi and one or more antigenic subunits from the non-crossprotective isolates, an adjuvant in an amount effective to enhance the immunogenicity of the inactivated Borrelia burgdorferi and antigenic subunits and a suitable carrier. Methods of immunizing an animal against Borrelia burgdorferi infection which comprise administering to the animal a dose of a bacterin provided herein are also provided.